Publicaciones científicas
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines
Pedro Berraondo 1 2 3 4 , Raquel Cuesta 1 2 , Miguel F Sanmamed 1 2 3 4 5 , Ignacio Melero 1 2 3 4 5 6
Abstract
In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected.
Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.
CITA DEL ARTÍCULO Cancer Discov. 2024 Nov 1;14(11):2021-2024. doi: 10.1158/2159-8290.CD-24-1196
Nuestros autores
